Single-arm Clinical Trial of TACE in Combination With Acoradine as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with Acoradine
Hepatocellular Carcinoma (HCC)
DRUG: TACE combined with Acoradine
1 year recurrence-free survival rate ,1-year RFSR., 1 year recurrence-free survival rate ,1-year RFSR., 1 year
TTR( time to recurrence), TTR( time to recurrence), 1year
To assess 1-year recurrence-free survival (RFS) in patients with hepatocellular carcinoma (HCC) who are at high risk of Inguinal orchiectomy recurrence usingTACE combined with Acoradine